Novo Nordisk says its insulin pump secures EMA marketing authorisation

pharmafile | June 28, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing |  EMA, Novo Nordisk, insulin pump, marketing, product launch 

Diabetes drugmaker Novo Nordisk (NYSE: NYO) said it has secured European Medicines Agency (EMA) marketing approval for its insulin pump. 

The product mylife YpsoPump will be used with prefilled pump cartridge NovoRapid PumpCart, the company said. 

Christian Kanstrup, senior vice president, marketing, medical affairs and stakeholder engagement at Novo Nordisk, said: “Our partnerships with Ypsomed and Roche Diabetes Care enable us to offer new options designed to simplify insulin pump therapy for people living with diabetes and the healthcare professionals who manage their care.” 

NovoRapid PumpCart contains NovoRapid (insulin aspart), a rapid-acting insulin from Novo Nordisk, and is a 1.6 ml prefilled pump cartridge specifically designed to make insulin pump therapy more convenient for some people with diabetes and the healthcare professionals caring for them. 

Mark Evans, lecturer and honorary consultant in medicine at the University of Cambridge, said: “Insulin pump therapy can be an effective option for helping some people with diabetes, particularly those living with type 1 diabetes, however, operating a traditional insulin pump, and manually filling the insulin reservoir, can be complex and time-consuming. Given these factors, and the burden put upon health systems to train patients to use traditional pumps, efforts to simplify the process are truly welcomed.” 

An insulin pump delivers insulin from a reservoir inside the pump to a patient’s body using an infusion set and a tiny cannula. 

Anjali Shukla